Sotagliflozin
| CAS No. | 1018899-04-1 | Cat. No. | BCP07416 |
| Name | Sotagliflozin | ||
| Synonyms | LX-4211; LX 4211;LX4211; | ||
| Formula | C21H25ClO5S | M. Wt | 424.94 |
| Description | Sotagliflozin, also known as LX4211, is an orally active and a dual SGLT1/SGLT2 inhibitor, which improves glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. Sotagliflozin is currently being developed by Lexicon for the treatment of type 1 and type 2 diabetes mellitus. Sotagliflozin may be an effective and promising medication for treating not only Type 2 diabetes (the common target for non-insulin medications for diabetes), but also Type 1 as well. | ||
| Pathways | Ion Channel/Membrane Transporter GPCR/G Protein | ||
| Targets | SGLT | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.